InsidersTradesSigma
Follow the GALECTIN THERAPEUTICS INCORPORATED share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €405.4m. The latest transaction was disclosed on 29 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Harold Shlevin. Every trade is openly available.
Analysts rate GALECTIN THERAPEUTICS INCORPORATED Strong Buy (bullish), based on 1 analysts. Average price target: US$11.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
GALECTIN THERAPEUTICS INCORPORATED es una empresa de biotecnología centrada en el desarrollo de tratamientos para enfermedades graves mediante la focalización en las galectinas, proteínas implicadas en diversos procesos patológicos.